Defiance CEO Says Yamo Pharma’s L1-79 ‘Life-Changing’ for Autistic Son

A biotech CEO publicly crediting an investigational drug with transforming his own child's condition is a potent narrative, but it sits awkwardly beside the clinical process. The Phase II trial remains the real arbiter of whether L1-79's observed benefits hold across a broader, less personal patient set. Because autism has no approved pharmacologic treatment, the FDA bar and the unmet need are both unusually high, which is precisely why anecdotal enthusiasm can outrun evidence. Whether trial data substantiate the CEO's account is the open question.